


PHARMACEUTICAL 2020

## BIOXYTRAN INC Rank 348 of 362







PHARMACEUTICAL 2020

BIOXYTRAN INC Rank 348 of 362

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,016% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 747% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,360%, being 1,058% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	220
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,019
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,124
Other Liabilities	0
Other Net Income	-227
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	507

Output Variable	Value in 1000 USD
Assets	220
Liabilities	1,019
Expenses	1,631
Stockholders Equity	-799
Net Income	-1,858
Comprehensive Net Income	-1,858
Economic Capital Ratio	-1,360%

